Cardiovascular Diseases Clinical Trial
To elucidate the biochemical, metabolic, and genetic markers and mechanisms of macrovascular disease in insulin dependent diabetes mellitus (IDDM).
BACKGROUND:
Macrovascular disease is the leading cause of death due to IDDM. Risk markers have been
identified in non-diabetic populations, but may not apply to IDDM. The theme of the program
project is that hyperglycemia interacts with specific factors to augment vascular risk and
establish novel mechanisms of atherogenesis.
Patients under study originally participated in the DCCT, a recently concluded NIKKD
clinical trial that demonstrated dramatic reductions in microvascular complications with
intensive glucose control. The DCCT, conducted from 1983 to 1993 in 1,441 insulin dependent
diabetes mellitus subjects at 209 medical centers, showed that keeping blood sugar levels as
close to normal as possible slows the onset and progression of eye, kidney, and nerve
diseases cause by diabetes.
The study is part of the initiative, The Etiology of Excess Cardiovascular Disease in
Diabetes Mellitus, which was released in December 1995. The initiative originated after
discussions between the NHLBI and the Juvenile Diabetes Foundation International (JDFI), a
voluntary organization that supports research on diabetes. Both agreed that a combination of
advances in understanding the etiology of diabetes and of cardiovascular diseases made this
an oppportune time to stimulate further research to understand the reasons for the excessive
macrovascular complications associated with diabetes.
DESIGN NARRATIVE:
In this program project grant, three of five subprojects are epidemiological studies. In the
first subproject, Glycoxidation and Macrovascular Disease in Diabetes, Timothy J. Lyons,
subproject principal investigator, investigates the mechanisms underlying accelerated
atherosclerosis in diabetes, specifically, the modification of lipids, proteins, and
carbohydrates by interrelated oxidation and glycation (glycoxidation). The cross-sectional
and longitudinal study uses approximately 900 Type 1 diabetic patients from the Epidemiology
of Diabetes Intervention and Complications Study (EDIC), a multicenter study which follows
patients from the Diabetes Control and Complications Trial (DCCT), both of which were
supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Cross-sectional studies are performed for a detailed analysis of potentially atherogenic low
density lipoproteins and triglyceride-rich lipoproteins in patients with and without
microalbuminuria and macrovascular disease. In a smaller cohort of the same patients,
categorized as prone or resistant to macrovascular disease, levels of glycation and
oxidation products are determined in insoluble skin collagen, a long-lived protein in which
modifications may reflect integrated glycoxidation over many years. In the longitudinal arm
of the study, characterizations of lipoproteins in selected patients are repeated in
selected patients who progress either to microalbuminuria or macrovascular disease. By
combining cross-sectional and longitudinal information, the investigators hope to identify
new markers to identify diabetic patients at particular risk of disease progression.
In Subproject 4, The Role of Thrombosis in Macrovascular Disease in IDDM, John Colwell as
subproject principal investigator, investigates abnormalities in hemostasis as contributors
to the excess cardiovascular morbidity and mortality associated with diabetes mellitus. Each
of 200 EDIC patient enrolled in the study and non-diabetic, control subjects are assessed
for endogenous fibrinolysis and are evaluated for prothrombin activation fragment F1+2 as an
index of thrombin generation and fibrinogen and hematocrit as basic hemorheologic
parameters. The studies are conducted cross-sectionally in the total EDIC cohort, and
longitudinally in selected EDIC patients whose diabetes either has not progressed or has
progressed to microalbuminuria or macrovascular disease. Hemostasis parameters are
correlated with other metabolic characteristics measured in the program project grant and
with PAI-1 and fibrinogen gene polymorphism.
In Subproject 5, Metabolic and Genetic Factors in IDDM Vascular Disease, W. Timothy Garvey
subproject principal investigator, investigates whether metabolic and genetic factors are
associated with the development of macrovascular disease or albuminuria in approximately 60
IDDM patients. The investigators have developed the concept, based on published and
pre-data, that patients with upper body fat distribution who become diabetic exhibit primary
abnormalities in fatty acid metabolism which secondarily exacerbate insulin resistance via
alterations in fatty acid composition of skeletal muscle membranes, vascular reactivity via
functional and structural changes in the vessel wall, and consequently vascular disease
risk. They are testing the hypothesis that, in patients with vascular complications, poor
glycemic control alters both circulating free fatty acids and fatty acid composition of
muscle membranes to enhance vascular reactivity and induce insulin resistance. They are
performing hyperinsulinemic glucose clamps in three IDDM subgroups (without complications,
with albuminuria, and with macrovascular disease) under conditions of poor glycemic control
and after intensive therapy to asses both glycemia-dependent and independent components of
insulin resistance. They are also testing the hypothesis that insulin resistance and
candidate gene polymorphisms determine in part which IDDM patients develop macrovascular
disease and albuminuria. They are assessing candidate gene polymorphisms in all DCCT
patients, and testing for linkage/association with macro- and microvascular disease
outcomes, as well as for abnormalities in encoded proteins.
The study was renewed in FY 2001 and is scheduled to end in 2006.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|